๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA ยท Real-Time Price ยท USD
23.22
-1.08 (-4.44%)
At close: Nov 20, 2026, 4:00 PM EST
23.17
-0.05 (-0.22%)
After-hours: Nov 20, 2026, 7:30 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

DMR-001 is advancing in a phase I/Ib study, with four-week SC dosing and preclinical potential across CALR mutation types. Strong patient and physician interest is driving global study expansion; management sees disease-modifying endpoints and monotherapy as important strategic themes.

Akash Tewari
Analyst, Jefferies

Alrighty. Thanks so much for joining us day three of our healthcare conference. My name is Akash Tewari. I head our pharma and biotech research efforts internally within Jefferies. I have the pleasure of hosting the Damora management team, and I am really looking forward to it. Why do I hand it off to you, Jennifer, for some opening remarks, and we will get to it.

Jennifer Jarrett
CEO, Damora

Yeah. First of all, I am Jen Jarrett. I am the CEO here of Damora, and this is Sherwin Sattarzadeh, who is the COO. This is actually the first time I have ever been to the London Jefferies Conference. I have been hearing about this for many, many years, so I am very excited to be here, and actually it has exceeded all of my expectations in terms of crowds and everything else. No, but it has been a great day, so thank you for having us. Damora is a Fairmount company. I am sure a lot of you guys are familiar with Fairmount companies. Like a lot of the other Fairmount companies, we were founded to develop molecules that came from the Paragon antibody platform. All of our molecules today came from Paragon.

I think Paragon has established a very well-deserved reputation for creating best-in-class antibodies, and we believe the antibodies in our portfolio are best in class. The antibodies that we are developing all target something called mutant CALR. Mutant CALR is a key driver mutation that is found in about one-third of patients with two different types of myeloproliferative neoplasms, so that is essential thrombocythemia and myelofibrosis. If you were to add up the number of patients in the U.S. that have that mutation, it is about 45,000 patients just in the U.S. So very big patient population. You were to apply kind of typical pricing for an MPN drug, and the market opportunity is well north of $10 billion in the U.S. alone.

This class of therapies is the first targeted therapy that addresses a key underlying driver of disease in MPNs, which is why there is so much excitement around this class of therapies. Our molecule, DMR-001, is our most advanced molecule. It is similar to another antibody that is in development called INCA033989, which is a molecule that Incyte is developing. They are only about two years ahead of us. It is similar to that molecule in two ways. First of all, like the Incyte molecule, it is Fc-null. The second similarity is it targets the same epitope. The reasons why we wanted to preserve those two things in our molecule is that Incyte's molecule has a very, very good safety and tolerability profile, so we wanted to replicate that. There are two key differences with our molecule, though. The first key difference is that we have a much better PK profile and half-life.

As a result, we expect to be able to administer our drug every four weeks by subcutaneous administration. That compares to INCA033989, which is currently being dosed every two weeks by IV. The second major difference with our molecule is that, based on our preclinical data, it appears like it will be very active against the type 2 mutation. These patients that have the CALR mutation can be classified either as type 1 or type 2. The market is probably split about 50/50 between those two patient populations. If you look at the INCA033989 data, the data looks really good in type 1, but they are seeing much less activity against patients that have the type 2 mutation.

Based on the preclinical data that we have generated, we believe that we are getting much better potency against the type 2 mutation, and so our drug should work better in those type 2 patient population. We are now full steam ahead with DMR-001 into our first clinical studies. This is a phase I/I-B study that we initiated just a little while ago. It is now open in Australia and the U.S. It is a pretty classic dose escalation expansion study. One thing that I would point out, though, that I think is special about the study is we are able to start at a relatively high dose.

Just given the fact that this is Fc-null, we target the same epitope as Incyte, so we were able to leverage all of the safety and tolerability data that they have generated to convince regulatory agencies that we should be able to start at this relatively high dose. So we are starting at 100 mgs every four weeks. We do believe that will be an active dose, which is always good, and it also limits the number of dose escalation cohorts that we will likely need to do before we start our expansion cohorts. I will stop there.

Akash Tewari
Analyst, Jefferies

No, that is excellent.

Jennifer Jarrett
CEO, Damora

open for questions.

Akash Tewari
Analyst, Jefferies

Thanks so much.

Jennifer Jarrett
CEO, Damora

Probably covered everything. No.

Akash Tewari
Analyst, Jefferies

I wish it was that simple. But I will say, actually, there is an element. It is very easy to understand the story, and I think that is why we have seen interest from Incyte, we have seen interest even from Lilly very recently. So I think that is actually very true. One of the things I would love to get your take on, why do you feel like there is so much interest in the CALR space? Because I think, and I am sure you had this question kind of two years ago, "Well, this does not seem like that is that many patients," and MF and ET, usually there is a long path to development, but that is really not been the case when we think about strategically what is occurring.

What does your team see that is special about CALR?

How is that kind of getting reflected externally as well?

Jennifer Jarrett
CEO, Damora

Yeah. Very good question. First of all, just starting with MPNs more broadly, I did not appreciate this, to your point, till I got to Damora, but there is just a lot of interest in MPNs, period. Most companies have built out an MPN capability by buying things. Bristol, Merck, Novartis, Lilly have all bought programs that got them into the MPN space. What is attractive about the MPN space is, first of all, it is a pretty large patient population. You do get premium pricing for these types of drugs. You get oncology-like drug pricing. The studies are actually pretty small and inexpensive, particularly relative to solid tumor studies. These patients live much longer, honestly, than sadly, a lot of solid tumors and even hematological cancers. So the expectation is that these patients can be on treatment for many years.

Interestingly, though, that does not really happen in practice with the JAK inhibitors. When you looked at the phase III study that was done with Incyte's JAK inhibitor, which was the first JAK inhibitor that was approved, ruxolitinib, patients were on treatment for about three years on average. So that is something that obviously got people excited about that class of drugs, because if patients are on treatment for three years at $250, whatever, $1,000 a year pricing, that is a pretty good NPV. In practice, though, what we hear is that patients are only on treatment for typically one year, and at that point, they just start to develop cytopenias and anemias, and they really just cannot stay on treatment. They cannot tolerate the treatment anymore, so they come off. Rux also does not address the underlying driver of disease.

Rux is pretty good at alleviating symptoms, reducing spleen size, but it does not address the underlying driver of disease, and it does not slow the progression of disease. That is what these patients fear the most, is just their bone marrow, in the case of myelofibrosis patients, becoming more and more fibrotic. In the case of ET patients, they worry about their symptoms getting worse and worse, and they worry about their disease progressing to myelofibrosis. ET is also a very similar story. Actually, the treatment options are even worse, and so HYDREA is the most commonly used treatment option, which is basically like a mild form of chemotherapy, so you get all the same side effects you expect with chemotherapy. Again, patients do not stay on HYDREA for extended periods of time.

What has gotten people excited about the mutant CALR antibody class is that you are addressing the key driver of disease in these patients, and it is a very safe and well-tolerated drug. It is so specific for this target. That is something that Incyte has shown, it is something that we have shown in our preclinical data, and we are seeing very, very good activity, particularly in ET. The MF data has also looked very robust. We will see more MF data at ASH, but when people look at the activity that they are seeing in type 1 patients with ET, you are getting an 80% plus complete hematological response rate, which is pretty incredible. So that is what has got people very excited about-

Akash Tewari
Analyst, Jefferies

Understood.

Jennifer Jarrett
CEO, Damora

-this class of drugs.

Akash Tewari
Analyst, Jefferies

Now, I think there is an element of, and we are seeing this a lot in healthcare, people can have similar assets. It is really, how do you, I would hate to, I will even use the word ruthlessly, but how do you definitively think about clinical development in a way that it just shuts the door for people who might be behind you? You do have a lead when you think about a molecule that can work in type 1 and type 2, but now you will also compete against companies with a lot of, they have GLP-1 money, is that-

Jennifer Jarrett
CEO, Damora

Yeah.

Akash Tewari
Analyst, Jefferies

-you'll often hear. But I feel like your team's really learned a lot from the Incyte data over the last year. What are those learnings that you're applying to your clinical development program, and how does it contrast to what Incyte's really going for both ET and MF?

Jennifer Jarrett
CEO, Damora

You want to?

Sherwin Sattarzadeh
COO, Damora

Yeah. The first thing that we've learned is just the level of interest at the physician and patient level for therapies that are going to have this disease-modifying potential. We started out understanding what the profile for INCA033989 looked like, laying out the argument for DMR-001 and how it's differentiated from its preclinical profile, and how we expect that to translate into the clinic. And sharing that story with physicians, we just see the amount of interest that they have in participating in the DMR-001 study.

This really started out as a clinical development program that had some sort of finite boundaries around the size of a program we thought we would embark on, and as we've talked to more and more physicians and patients, just the amount of interest has led us to really expand this study to be a global phase I study across a number of sites geographically that is going to allow us to go quickly. The other thing that we've learned is mutant CALR patients know that they're mutant CALR patients, so they advocate for access to better treatment options in a way that I think in a lot of other disease areas you don't see that.

The interest that we get from patients even reaching out to us and/or through their physicians, that, When is DMR-001 going to be open at my site that I can have access to this as well? The reason for that is that they understand that with the great data that Incyte has put out, the limitations that it does have and the convenience barriers of the every two-week IV infusion, the lack of similar potency on the type 2 mutation, which is a sizable proportion of the population, as you said. This sort of unmet need is becoming clearer to the broader community and where DMR-001 can really fill that. We're using those as means to really set up this program to go quickly, to go broadly, to generate the data we need to pivot quickly to phase III.

Akash Tewari
Analyst, Jefferies

Understood. Now, I think one of the other things that I know your team is looking, I know we're also looking at, is really regulatory feedback that Incyte's gotten about kind of endpoint selection in a second-line setting, but then I think the other question becomes in a first-line setting as well. Now, what's your kind of view? Let's say that we're in a world where what the second-line endpoint is, where there is an acknowledgment of anemia benefit, and that is a secondary endpoint, but it's not necessarily a dual primary endpoint. How does that change your regulatory development path in front-line and second-line MF, or does it not change it either way? Because in the end of the day, by having it even as a secondary endpoint, it acknowledges the fact that the FDA is taking that into account, right?

Are we overthinking the importance of this being a primary versus a secondary endpoint here?

Jennifer Jarrett
CEO, Damora

You do mean VAF?

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

Okay. Yeah, one thing to say, VAF is what, and I know you know this, what the CALR community's really been advocating for.

They really feel like VAF is your evidence of disease modification because it shows you're eradicating the mutant clone and therefore, the disease is going away and you're really stopping the progression of the disease. That's why I do think, if you have it as a secondary endpoint and it's on your label, I do think that's really important from a commercialization perspective, because I think it just highlights the importance of therapies, and I think will be very meaningful to the clinicians-

-that are prescribing that therapy, as well as payers. I do think having VAF, even if it's just as a secondary endpoint, is really important. One thing that's interesting, in ET, Incyte has said that the FDA was actually the ones that suggested that they include VAF as a secondary endpoint. The FDA is, I think, starting to recognize the importance.

Even if the MF, they're clearly not quite there. I do think KOL community is going to continue to push to figure out how VAF can get incorporated as an endpoint, and how you maybe start to get away from the symptom score as a key endpoint.

Akash Tewari
Analyst, Jefferies

Does that change your trial design or your assumption for kind of first line or no?

Jennifer Jarrett
CEO, Damora

Yeah.

Akash Tewari
Analyst, Jefferies

The point is, because we will often get this with investors, the more typical TSS50 endpoints that we will see, is your team confident that there is a place even with that metric alone, whether it is in monotherapy and in combo with CALR?

Sherwin Sattarzadeh
COO, Damora

Yeah. I think, and I will answer your question in a second, but I think we also have to view this in terms of what is necessary for demonstration of an approvable data set-

Akash Tewari
Analyst, Jefferies

Yeah.

Sherwin Sattarzadeh
COO, Damora

-from a regulatory standpoint versus how a product ultimately gets used based on the totality of evidence there. The endpoints we currently have are for agents that do not have disease-modifying potential. They were designed for the attributes of the drug that demonstrates improvement on those types of endpoints, like symptoms. Whereas when you have something like a mutant CALR disease-modifying directed therapy, it is going to take time for the regulatory science to catch up with the evolving clinical science.

to a place where we can actually then employ those endpoints for regulatory decision-making. That's not to say that the broader community is failing to understand the benefit that targeted therapy is going to bring for patients. Now, how do you incorporate that into your development program? Very happy that Incyte is continuing to push with the volume of data that they've been generating to have that discussion with the FDA, to push them to evolve beyond the classic TSS, SVR endpoints. In fact, there was an International Working Group-Myeloproliferative Neoplasms Research and Treatment that was held in D.C. about a month or so ago between industry, FDA officials, and KOLs. The amount of interest and vocalness that the KOLs were presenting to FDA, the importance of moving towards these VAF, these anemia benefits, and really trying to move the needle away from TSS as a primary endpoint in these patients.

The way that they use VAF in order to even treat their patients and understand if their patients are benefiting or not benefiting from a therapy. I think this is just the evolution that is going to take a little bit of time, and Incyte will be leading that effort.

By the time it's our turn to have those similar conversations, the FDA's thinking will have evolved to a point where perhaps we have a better opportunity to move that.

Akash Tewari
Analyst, Jefferies

Understood. Kind of a bridge to this, it's interesting. We focus so much about Incyte's discussion with CALR, but I think there's an equally instructive case study with GSK and Momo, right? I mean, first of all, that's, A, a recognition that the FDA That's a lower SVR rate-

Sherwin Sattarzadeh
COO, Damora

Yeah.

Akash Tewari
Analyst, Jefferies

t-han Jakafi.

Sherwin Sattarzadeh
COO, Damora

Yeah.

Akash Tewari
Analyst, Jefferies

They still found a path to get onto the market in frontline. That is an acknowledgment that anemia benefits are critically important. That was a different trial design

than what we have seen with some of the JAKs that have come recently. How much have you learned from Momo's frontline development, I am going to call it that you might be able to apply with your program?

Jennifer Jarrett
CEO, Damora

I think, when you look at, and we have talked to FDA a lot about this. I mean, if you look at all the MF studies that have been done, I would say what has probably been used the most is a sole primary of SVR and then a key secondary of TSS50. But as you pointed out, there has also been some variation-

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

-including what GSK did or Sierra did with momelotinib. I think that does show there's flexibility. We'll continue to figure out what we think are the best endpoints for this class of therapies. There's a lot of different opportunities and options, I think, out there. We will figure out what's best for us. I do think, if you look at the SVR35 data that's been presented so far for 989, we'll see more data obviously at ASH.

It feels like either in the second-line setting or frontline setting in the type 1 patient population, they should beat Ruxo or whatever the control arm is pretty meaningfully. Especially since they said that patients that have the CALR mutation that get ruxolitinib do meaningfully worse versus the non-mutant CALR patients, which tells you the 40%.

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

Or 30% comfort is not the real number. It's really more like 20%. I also think if you did end up with SVR35 and TSS50, I still think you have a very good shot to succeed. There still may be better endpoints that really capture the benefits of this class of therapies, like anemia benefits, you're pointing.

Akash Tewari
Analyst, Jefferies

Very much agree on both fronts. Lilly acquired a company that is in a similar area of development as you. Behind, though. It's interesting. We were kind of thinking about this internally when we were looking at it. Lilly has a selective JAK1, JAK2. It's shown interesting data, but I think your team's been very insistent, and I think rightfully so, that there are distinct places for JAK inhibitors and CALR.

We were kind of thinking about this too. That JAK selective that they got from Ajax, really nice response rates, but you still had a lot of anemia, and you still had heme tox. This is your guess is as good as ours. Do you feel like the acquisition from Lilly is a combo? It is a sign that actually combination approach is really the right place? Or is it actually a sign that, no, it is a recognition that CALR in of itself is a distinct market in MF and ET? You are going to, I guess-

Jennifer Jarrett
CEO, Damora

It is probably.

Akash Tewari
Analyst, Jefferies

-take a guess.

Jennifer Jarrett
CEO, Damora

I mean, I do think-

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

-they have been interested in mutant CALR. I think they've been vocal about that. I do think they were also interested in combining mutant CALR antibody with their JAK inhibitor, because if you remember, in the data that they presented at EHA, they had very good activity. You look at VAF, which was the only data where they really broke out efficacy by mutation. They saw very good VAF reductions in patients with JAK2V617F, but almost no VAF reduction in patients with mutant CALR. Again, makes that point that these selective JAK inhibitors don't perform as well in mutant CALR patient or do as much as in mutant CALR patient. But your point, I think it's a bit of both. I think they like this target, as do, I think, a lot of people.

I do think they wanted something to combine with the drug that they got from Ajax. I do also think, and this is something else we'll see at ASH, that there's still some question about whether a combination or monotherapy strategy is the right strategy for mutant CALR antibody in the frontline. I think there's a lot of different views. I do think probably the predominant view is that monotherapy is probably better.

Because so far, the combination data seems to show that there's not a ton of added efficacy when you add Rux, but you are bringing additional toxicity. So again, we'll see what the latest data shows, but I think if Lilly does go the direction of combining the Ajax molecule with the Calytrix molecule, that's just something to keep an eye on.

Akash Tewari
Analyst, Jefferies

Understood. I think, can you walk a bit about, you have a drug that works in type 1 and type 2.

What does that allow you from a powering perspective, a trial design perspective, that not only, let's say, makes your clinical path to market simpler, but actually maybe allows more certainty for getting to market quickly? How does the agency think about this too?

Sherwin Sattarzadeh
COO, Damora

Yeah, I mean, the target product profile we're pursuing for DMR-001 is one that has a single dose regardless if it's a type 1 patient or a type 2 patient.

Ideally, regardless if it's an ET patient or an MF patient. What that affords you is to sort of not go through the complexities that INCA033989's phase III study designs have had to do, which in ET has a single titration step up for patients based on their platelet counts at day 15. Everybody starts at 750 milligrams every two weeks, goes up to 2,500 milligrams, as a means to capture the non-type one patients to give them an opportunity to have a better response rate. You're essentially ending up with four different patient populations at the end that you're going to have to decide how you're going to statistically test for between two populations and two dose levels.

On the myelofibrosis second line study, they're enrolling all patients, but have designed the study to statistically test for type 1 patients first, given their lower activity in the non-type one population or the type 2 population. In the product profile we're pursuing, it just simplifies a lot of those things. Your statistics are based on a response rate estimate at a dose. It just becomes that much simpler, and potentially smaller studies to demonstrate the phase III efficacy and safety.

Akash Tewari
Analyst, Jefferies

Understood. When you think about combo versus monotherapy, you mentioned what we've seen in MF. Can you talk a bit about ET as well, what do you think will ultimately be the paradigm in a frontline setting? Do you think combination is even the right approach here, or is it really going to be about monotherapy CALR?

Jennifer Jarrett
CEO, Damora

Yeah, I think in ET in particular, especially since there's not an obvious combination partner.

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

I think everyone wants to get away from HYDREA versus figure out, how do you just go on top of HYDREA? Yeah, I think, when you look at the type 1 monotherapy data, it looks very strong. It's type 2 where you're not seeing the activity that you'd ideally like to see. So, it also just, when you look at the data, it doesn't seem to suggest you need to add something to mutant CALR antibody to get the activity.

Akash Tewari
Analyst, Jefferies

Understood. Now, I'd love your take too, as you get longer duration on treatment. We're looking at some of these anemia endpoints, but we think about them maybe statically. I don't think we're thinking about it from a long-term perspective. Do you have a view on what could really, with CALR, potent CALR, sustained inhibition over a period of time, deliver in terms of functional outcomes for some of these patients that we're not really talking about right now?

Jennifer Jarrett
CEO, Damora

Yeah, I think, when we talk about our base case TPP, we are assuming for now, our type 1 activity looks similar to INCA033989. I do think there is some possibility that because we are getting much better target coverage, like when you look at their PK curve.

They have never disclosed their PK curves in humans, so this is just based on non-human primate data. It is a little bit unclear if they are really covering the target for the full 14-day period of their dosing interval. With our drug, we do think we are going to get complete coverage, or the complete coverage, over the course of the dosing interval. You do wonder, will that translate into better efficacy, like in type 1 MF, where maybe there is still leaving a little bit of efficacy on the table? Relative to ET, it feels like they are getting a lot out of this mechanism in a type 1 ET patient. But type 1 MF patients, maybe there is still a little bit of efficacy that is left on the table.

So, at least we will run the experiment and see if covering the target better over a longer period of time, does that result in better efficacy in those type 1 MF patients?

Akash Tewari
Analyst, Jefferies

Understood. Maybe just lastly, I think, not just you, but other players in this space have talked about, Hey, we look at momelotinib, anemia benefit might be an interesting combination partner. But I know your team is looking at the entire gamut, and even if you look at your own portfolio, you are looking at CALR and you are cutting it three different ways. Are there other emerging datasets, other interesting biology which you feel like would be potentially synergistic with CALR beyond just simply JAK inhibition that you are really excited about?

Jennifer Jarrett
CEO, Damora

No.

Akash Tewari
Analyst, Jefferies

Might be too. Okay.

Jennifer Jarrett
CEO, Damora

Honestly, no.

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

Yeah. I mean, there's really not a lot going on in this space.

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

As part of it, like the other class of drugs is the LSD1 inhibitors. Which Merck is developing in ET, but it's not a great tolerability profile. I think there's a lot of questions about how well utilized that class of drugs is going to be in ET. Again, we really love the safety and tolerability profile of INCA033989 and what we expect our drug to have, so we don't love the idea of combining with something that then diminishes that safety and tolerability profile. I was asking when we were talking to one KOL last week, and he said he'd just been asked by someone what side effects he sees in patients that are on INCA033989, because he's had a lot of patients on INCA033989. He said, I literally could not think of one thing.

Which is really unusual. I mean, this is like a heme cancer drug, and the fact that you're really not seeing anything that stands out from a side effect profile. We do want to really preserve that, and that's what makes any combination challenging.

Akash Tewari
Analyst, Jefferies

Understood. I do think that's important is, again, I think your team has the opportunity to really shut the door.

Jennifer Jarrett
CEO, Damora

Totally. Yeah. In ET, you want these patients, I mean, these patients live for 20, 30 years. You want these patients to be on treatment for as long as possible. The other thing that tends to happen with combinations is that it's just harder, especially as you see more toxic, keep patients on both treatments. Patients start to discontinue one treatment or both treatments. Because of that additional toxicity. you are losing efficacy, so that is just the other challenge when you are combining things.

Akash Tewari
Analyst, Jefferies

Understood. I did not expect that answer, but I appreciate it.

Jennifer Jarrett
CEO, Damora

No. Okay, but we do like the idea of combining JAKs.

Akash Tewari
Analyst, Jefferies

Makes a good point.

Jennifer Jarrett
CEO, Damora

to be clear.

Akash Tewari
Analyst, Jefferies

Yeah.

Jennifer Jarrett
CEO, Damora

There's some JAKs out there that we like and whatever. I'll end there.

Akash Tewari
Analyst, Jefferies

On that note, hey, thank you so much. I really do appreciate it.